关键质量属性
过程开发
工作流程
生物过程
设计质量
过程(计算)
生化工程
过程分析技术
药物开发
计算机科学
生物制药
质量(理念)
新产品开发
工艺验证
工艺工程
过程管理
色谱法
风险分析(工程)
化学
药品
生物技术
业务
医学
工程类
药理学
数据库
生物
营销
认识论
哲学
化学工程
操作系统
作者
Jia Guo,Regina Kufer,Delia Li,Stefanie Wohlrab,Midori Greenwood‐Goodwin,Feng Yang
出处
期刊:mAbs
[Landes Bioscience]
日期:2023-05-22
卷期号:15 (1)
被引量:6
标识
DOI:10.1080/19420862.2023.2213365
摘要
Host cell proteins (HCPs) are process-related impurities derived from the manufacturing of recombinant biotherapeutics. Residual HCP in drug products, ranging from 1 to 100 ppm (ng HCP/mg product) or even below sub-ppm level, may affect product quality, stability, efficacy, or safety. Therefore, removal of HCPs to appropriate levels is critical for the bioprocess development of biotherapeutics. Liquid chromatography-mass spectrometry (LC-MS) analysis has become an important tool to identify, quantify, and monitor the clearance of individual HCPs. This review covers the technical advancement of sample preparation strategies, new LC-MS-based techniques, and data analysis approaches to robustly and sensitively measure HCPs while overcoming the high dynamic range analytical challenges. We also discuss our strategy for LC-MS-based HCP workflows to enable fast support of process development throughout the product life cycle, and provide insights into developing specific analytical strategies leveraging LC-MS tools to control HCPs in process and mitigate their potential risks to drug quality, stability, and patient safety.
科研通智能强力驱动
Strongly Powered by AbleSci AI